Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ainos Inc AIMD

Healthcare Biotechnology
Ainos, Inc. is engaged in developing medical technologies for point-of-care (POCT) testing and medical treatment for a range of disease indications. The Company is engaged in the research and clinical development activities for its programs, securing related intellectual property, and commercializing therapeutics using low-dose non-injectable interferon (IFN). Its Medtech solutions includes COVID-19 Antigen Rapid Test Kit, Volatile Organic Compounds (VOC) POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha (VELDONA) and Synthetic RNA (SRNA). Its Ainos Flora device is intended to perform a non-invasive test for female vaginal health and certain common sexually transmitted diseases (STDs). Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia.


NDAQ:AIMD - Post by User

Ainos Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by CashSeekeron Dec 04, 2024 8:17am
34 Views
Post# 36344693

$AIMD

$AIMD 1. Big news! Ainos, Inc. is partnering with Taiwan Tanabe Seiyaku to introduce VELDONA® in Taiwan for Sjgren's syndrome. This condition, affecting 1% globally, causes dry eyes and mouth, with current treatments only managing symptoms. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
2. Major milestone! The MOU between Ainos and Taiwan Tanabe Seiyaku kickstarts Ainos' Veldona outlicensing strategy. This partnership aims to accelerate the market entry of innovative treatments. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #DrugOutlicensing #OrphanDrug #PharmaDeals #PharmaPartnerships #RareDisease #SjogrensSyndrome
3. Promising results! Ainos' VELDONA® is showing great potential in clinical trials for Sjgren's syndrome, a condition affecting 1% globally with no curative therapy. Read more: https://www.newsfilecorp.com/release/231739/Ainos-Inc.-Announces-Strategic-Partnership-with-Taiwan-Tanabe-Seiyaku-to-Advance-Manufacturing-and-Taiwan-Market-Promotion-of-Sjgrens-Syndrome-Drug #AinosInc $AIMD #AIMD #Veldona #Biotechnology #AutoimmuneDisease #ClinicalTrial #RareDisease #SjogrensSyndrome
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities